Pharmaceutical Technology

OCTOBER 14, 2022

US-based pharmaceutical companies Enliven Therapeutics and Imara have entered a definitive merger deal in an all-stock transaction to advance oncology product candidates. Once the merger has closed, a clinical-stage biopharmaceutical company will be created that will operate under the name Enliven Therapeutics.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 2, 2022

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. By 2026, the report predicts that each of the top 10 selling orphan drugs will earn between $3 billion and $13 billion.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MARCH 30, 2022

The building – which will be designed by Kadans – is expected to be open for business in 2026, and according to a Financial Times report is expected to cost around £500 million ($657 million) to construct. ” The project has been announced after the UK life sciences sector enjoyed a record year for investment, raising £4.5

Pharmaceutical Companies 57

Pharmaceutical Companies Pharmaceutical Companies 57

pharmaphorum

JANUARY 10, 2023

This is a golden opportunity for pharmaceutical companies to deploy the power of data and digital to laser-focus delivery across its client base, ultimately improving the value of engagements and capturing market share, says Treasure Data founder and CEO Kazuki Ohta. Capturing market share. billion in 2021 to $9.23

Compounding 98

Compounding Insurance Pharmaceutical Companies Pharmaceutical Companies 98

ISPE

SEPTEMBER 29, 2023

Takeda is the first pharmaceutical company worldwide to have implemented this water preservation project, in collaboration with a Belgian start-up Ekopak, on a large scale. By 2026, the site will produce 80% of its electricity consumed on-site and aims to be a net-zero greenhouse gas emissions site by 2030.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Patient Care 52

STAT

MARCH 7, 2024

A federal judge in New Jersey heard an unusual quadruple oral argument in which attorneys for all four drug makers combined forces to challenge different facets of the Inflation Reduction Act, which in 2022 empowered Medicare to negotiate the prices of a small number of drugs each year beginning in 2026.

Pharmaceutical Companies 136

Pharmaceutical Companies Pharmaceutical Companies 136

Pharmaceutical Technology

JANUARY 10, 2023

There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets.

Labelling 52

Labelling Compounding Pharmaceutical Companies Pharmaceutical Companies 52

PharmaShots

FEBRUARY 21, 2023

With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market. With the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026.

FDA 56

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 56

STAT

FEBRUARY 1, 2024

… The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, but declined to disclose any details , STAT tells us. Companies have until March 2 to either accept the government’s offer or propose a counteroffer.

Pharmaceutical Companies 101

Pharmaceutical Companies Pharmaceutical Companies 101

Pharmaceutical Technology

APRIL 28, 2023

The company undertook several initiatives recently to expand its business through new partnerships, expansion of existing relationships, and investment in manufacturing capacity. Key among them has been the extension of Syngene’s research collaboration with leading biotech company Amgen Inc. until 2026.

FDA 52

FDA Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry. appeared first on.

HIV Treatment and Prevention Agents 57

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 57

pharmaphorum

JANUARY 6, 2022

IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.

Vaccines 109

Vaccines Pharmaceutical Companies Pharmaceutical Companies 109

Omnicell

JANUARY 10, 2023

Starting next year, Medicare will negotiate directly with pharmaceutical companies to set the maximum fair price (MFP) for certain prescription drugs, with the application of the negotiated prices starting in 2026 for 10 negotiation-eligible drugs from Part D. In practice, Medicare will be able to dictate those prices.

Hospitals 52

Hospitals Omnicell Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

FEBRUARY 16, 2022

Faster is just one of the areas of focus for NICE as set out in their five year strategy , running from 2021 to 2026. Ensuring wider use of new medicines is what will make the UK market really attractive to pharmaceutical companies. months on average from marketing authorisation to final NICE output in 2020/21.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.

Pharmaceutical Companies 64

Pharmaceutical Companies Pharmaceutical Companies Communication Hospitals 64

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Hospitals 52